Pacific Biosciences Of California (PACB) Net Income towards Common Stockholders (2010 - 2026)

Pacific Biosciences Of California's Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$8.3 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 98.06% year-over-year to -$8.3 million; the TTM figure through Mar 2026 stood at -$128.6 million (up 80.45% YoY), while the FY2025 annual figure was -$546.4 million, down 76.34% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$8.3 million, up from -$40.4 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $2.4 million in Q4 2024, with the low at -$426.1 million in Q1 2025.
• The 5-year median for Net Income towards Common Stockholders is -$71.4 million (2022), against an average of -$87.4 million.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders soared 102.89% in 2024, then slumped 1802.7% in 2025.
• Pacific Biosciences Of California's Net Income towards Common Stockholders stood at -$84.4 million in 2022, then gained by 2.8% to -$82.0 million in 2023, then jumped by 102.89% to $2.4 million in 2024, then plunged by 1802.7% to -$40.4 million in 2025, then jumped by 79.5% to -$8.3 million in 2026.
• Business Quant data shows PACB's Net Income towards Common Stockholders at -$8.3 million in Q1 2026, -$40.4 million in Q4 2025, and -$38.0 million in Q3 2025.